Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors.

ABSTRACT:

Background and aims

Analysed using classical frequentist hypothesis testing with alpha set to 0.05, the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) did not find enough evidence to reject the hypothesis of no difference in neuropsychiatric adverse events (NPSAEs) attributable to varenicline, bupropion, or nicotine patch compared with placebo. This might be because the null hypothesis was true or because the data were insensitive. The present study aimed to test the hypothesis more directly using Bayes factors.

Design

EAGLES was a randomised, double-blind, triple-dummy, controlled trial.

Setting

Global (16 countries across five continents), between November 2011 and January 2015.

Participants

Participants were smokers with (n = 4116) an

SUBMITTER: Beard E 

PROVIDER: S-EPMC8612131 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature